No Data
No Data
William Blair Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
Buy Rating on PROCEPT BioRobotics: Attractive Entry Point Amidst Growth Potential and Upcoming Clinical Catalysts
Top Executives Unload Major Shares in PROCEPT BioRobotics!
Procept Biorobotics Insider Sold Shares Worth $975,810, According to a Recent SEC Filing
The prospects for embodied AI are broad! A report from Morgan Stanley: focusing on the humanoid robot disruptor Mentee, the China and U.S. markets nurture a trillion-dollar opportunity.
Morgan Stanley has released the latest research report, exploring how embodied AI can help the humanoid robot market reach new heights, with a focus on the Israeli startup Mentee Robotics.
Jefferies Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating, Maintains Target Price $77